Finerenone (BAY-948862) is a nonsteroidal antagonist of the mineralocorticoid receptor (MR) (IC50=18 nM) with selective and oral activity. Finerenone is used in the treatment of patients with chronic kidney disease with type 2 diabetes.

Mineralocorticoid receptor:18 nM

METHODS: Human smooth muscle cells SMC and human endothelial cells EC were treated with aldosterone (1-50 nM) and Finerenone (1-10 nM) for 24 h. Cell proliferation was detected by BrdU incorporation assay.
RESULTS: After stimulation with aldosterone, the proliferation rate of SMC increased significantly. Although treatment with 1 nM concentration of Finerenone showed a clear tendency to decrease the SMC proliferation rate, 10 nM Finerenone adequately and significantly blocked aldosterone-induced SMC proliferation. However, aldosterone did not affect EC proliferation in vitro, nor did Finerenone. [1]
METHODS: HK-GFP-hMR cells were treated with aldosterone (10 nM) and Finerenone (1 µM) for 3 h. The gene expression levels were measured by RT-qPCR.
RESULTS: Finerenone was effective in antagonizing some aldosterone-induced genes. [2]

METHODS: To investigate the effects on vascular remodeling after acute vascular injury, Finerenone (1-10 mg/kg) was administered orally once daily for 21 days to wire-induced femoral artery dilated C57BL/6 mice.
RESULTS: Finerenone treatment inhibited intimal and intermediate cell proliferation after wire-induced injury in mouse femoral arteries at 10 days post-injury and attenuated the formation of neoplastic intimal injury at 21 days post-injury. [1]